



Gerald Spöttli

Contact

Gerald Spöttli

Publications (5)

Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer C. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. *Endocr Relat Cancer* 2012; 19:423-34.

Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer C. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. *Cancer Lett* 2010; 295:100-9.

Zitzmann K, Brand S, De Toni E, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. *Cancer Res* 2007; 67:5025-32.

Zitzmann K, De Toni E, Brand S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. *Neuroendocrinology* 2007; 85:54-60.

Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. *Biochem Biophys Res Commun* 2006; 344:1334-41.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch